Cambridge, United States
GentiBio, Inc., founded in 2020, is an innovative biotherapeutics company that has quickly positioned itself as a leader in developing engineered regulatory T cells, known as EngTregs. The company's slogan, "We make Tregs. Better.", encapsulates its mission to enhance existing Treg therapeutic solutions by deploying cutting-edge technology and pioneering advancements in Treg biology and synthetic immunology.
The startup is uniquely focused on addressing autoimmune, alloimmune, autoinflammatory, and allergic diseases, providing a novel approach to the challenges faced by traditional immune therapies. Utilizing both autologous and allogeneic platforms, GentiBio aims to restore immune tolerance, making significant strides in immune system regulation.
While concrete investment details remain undisclosed, the company's potential rests on its foundational expertise and innovative platform, marking it as a promising prospect for investors interested in transformative healthcare solutions amidst an evolving biotherapeutics landscape.
